ATNM's stockholders equity collapsed 76% from $32.8M to $7.8M while cash burned down 34% to $48.0M, indicating severe financial distress for this clinical-stage company.
The dramatic equity decline combined with substantial cash burn creates significant going concern risks for this clinical-stage biopharmaceutical company. With operating cash flow losses of $24.6M annually and current cash of $48.0M, ATNM has roughly two years of runway remaining, requiring additional financing or strategic alternatives to continue operations.
ATNM's financial position deteriorated significantly with stockholders equity plummeting 76% and cash declining 34% to $48.0M, while total assets contracted 33%. Although operating losses improved modestly (operating income improved 14% and R&D expenses decreased 30%), the company continues burning substantial cash with negative $24.6M in operating cash flow. The overall picture signals acute financial distress requiring immediate capital raising or strategic action to ensure business continuity.
Capital expenditure jumped 845.5% — major investment cycle underway; assess returns on deployment.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
Cash declined 34.2% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Current assets declined 33.7% — monitor working capital adequacy and short-term liquidity.
Total assets contracted 32.7% — asset sales, write-downs, or balance sheet optimization underway.
R&D spending cut 29.7% — could signal cost discipline or concerning reduction in innovation investment.
Operating cash flow grew 25.7% — strong conversion of earnings to cash, healthy business fundamentals.
Operating income improving — cost discipline or growing revenue base absorbing fixed costs.
Net income grew 11.4% — bottom-line growth signals improving overall business health.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →